Study closes debate on folic acid and heart disease

February 23, 2012
Taking folic acid doesn’t lower risk of heart disease

(Medical Xpress) -- Taking folic acid supplements is not going to have any meaningful effect on your risk of coronary heart disease.

That’s the conclusion of a comprehensive study led by Oxford University researchers that pretty much closes the door on this debate once and for all.

The possibility that folic acid might help prevent heart disease has attracted considerable interest over the last two decades – understandably, because folic acid pills would have been an attractive, simple and cheap measure to reduce people’s heart disease risk. But studies have often provided conflicting evidence on whether it helps.

Folic acid lowers levels of the amino acid, homocysteine, in the blood. It was thought that this would be beneficial because raised levels of homocysteine have been linked with coronary heart disease.

However, the Oxford researchers recently reported that taking folic acid supplements has no effect on reducing heart disease risk, through a large meta-analysis of data from randomised clinical trials.

Now, in a large-scale genetics study published in PLoS Medicine, they and their colleagues demonstrate that the reasoning behind the interest in folic acid doesn’t hold either: there is no link between high homocysteine levels and your likelihood of developing coronary heart disease.

With the evidence from genetic studies and clinical trials both arguing against the use of , the researchers say the debate is over.

"After two decades of research, this report provides a definitive answer to this question and refutes the relevance of use of folic acid for primary prevention of coronary heart disease," states Dr. Robert Clarke of the Clinical Trial Service Unit at Oxford University, who led the study.

The international group of researchers involved in the new study were interested to understand whether people whose genes lead them to have slightly higher levels of homocysteine throughout life have any extra risk of coronary heart disease.

The MTHFR gene encodes an enzyme which metabolises homocysteine, removing it from the body. But a single change in the DNA code, inserting a T for a C, reduces the enzyme’s efficiency.

Individuals with two copies of the altered gene have homocysteine levels that are about 20% higher than those with the more common gene variant.

This makes the gene a very good tool for studying whether homocysteine levels influence coronary heart disease risk.

However, the research team found that among 48,000 individuals with coronary heart disease and 68,000 controls, people who had the MTHFR gene variant did not have an increased risk of developing coronary heart disease.

The major new step taken by the researchers was to include 19 previously unpublished datasets involving 48,000 additional coronary heart disease cases in their analysis.

It was these unpublished data that drove the conclusion that high homocysteine levels do not have any effect on coronary .

The researchers suggest that publication bias (where more positive results tend to get published in scientific journals over negative findings) played a role in previous suggestions linking homocysteine with risk, together with methodological problems in some studies.

Homocysteine is produced in the body from methionine, an essential amino acid found in large amounts in meat, eggs and milk.

"Some believed that elevated homocysteine causes damage to the inner lining of blood vessels," explains Dr. Clarke. "However, elevated homocysteine levels are closely correlated with known risk factors, such as smoking, high blood pressure and high cholesterol. In retrospect, elevated homocysteine levels are probably a marker of cardiovascular disease rather than being causal."

The study was funded by the British Heart Foundation and UK Medical Research Council.

Explore further: High blood homocysteine levels are not linked with coronary heart disease

Related Stories

High blood homocysteine levels are not linked with coronary heart disease

February 21, 2012
A comprehensive study in this week's PLoS Medicine shows levels of the amino acid, homocysteine, have no meaningful effect on the risk of developing coronary heart disease, closing the door on the previously suggested benefits ...

Folic acid no help for heart and blood vessels

May 12, 2011
Folic acid does not reduce the risk of getting cardiovascular diseases, reports a three-year study of more than eight hundred people by Wageningen University. The results have been published in the American Journal of Clinical ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.